A number of research firms have changed their ratings and price targets for Iovance Biotherapeutics (NASDAQ: IOVA):

  • 12/14/2017 – Iovance Biotherapeutics was given a new $16.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 12/14/2017 – Iovance Biotherapeutics was given a new $13.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/13/2017 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $18.00 price target on the stock.
  • 12/6/2017 – Iovance Biotherapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 11/13/2017 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
  • 11/13/2017 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $18.00 price target on the stock.
  • 11/13/2017 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $13.00 price target on the stock.
  • 11/3/2017 – Iovance Biotherapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “
  • 11/1/2017 – Iovance Biotherapeutics had its price target raised by analysts at B. Riley from $17.50 to $18.00. They now have a “buy” rating on the stock.
  • 10/31/2017 – Iovance Biotherapeutics was given a new $13.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/30/2017 – Iovance Biotherapeutics was given a new $16.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/29/2017 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 10/25/2017 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at FBR & Co. They now have a $17.50 price target on the stock.

Shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) traded down $0.05 during mid-day trading on Wednesday, reaching $8.90. 155,842 shares of the company’s stock were exchanged, compared to its average volume of 382,534. Iovance Biotherapeutics Inc has a one year low of $4.45 and a one year high of $9.54.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). equities analysts predict that Iovance Biotherapeutics Inc will post -1.37 EPS for the current fiscal year.

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Receive News & Ratings for Iovance Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.